From Leflunomide to Teriflunomide: Drug Development and Immuno-suppressive Oral Drugs in the Treatment of Multiple Sclerosis

BACKGROUND: Immunosuppressive drugs have been used in the treatment of multiple sclerosis (MS) for a long time. Today, orally available second generation immunosuppressive agents have been approved or are filed for licensing as MS therapeutics. Due to semi-selective targeting of cellular processes,...

Descripción completa

Detalles Bibliográficos
Autores principales: Aly, Lilian, Hemmer, Bernhard, Korn, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652031/
https://www.ncbi.nlm.nih.gov/pubmed/27928949
http://dx.doi.org/10.2174/1570159X14666161208151525

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652031/
https://www.ncbi.nlm.nih.gov/pubmed/27928949
http://dx.doi.org/10.2174/1570159X14666161208151525

Ejemplares similares